Elsevier

Neuropharmacology

Volume 44, Issue 6, May 2003, Pages 787-800
Neuropharmacology

AM-36, a novel neuroprotective agent, profoundly reduces reactive oxygen species formation and dopamine release in the striatum of conscious rats after endothelin-1-induced middle cerebral artery occlusion

https://doi.org/10.1016/S0028-3908(03)00068-6Get rights and content

Abstract

Elevated generation of reactive oxygen species (ROS) has been demonstrated during ischemia and reperfusion. Dopamine (DA) autooxidation may contribute to increased ROS generation. The novel neuroprotective agent AM-36 has antioxidant and Na+ channel blocking activity and reduces neuronal damage in both cortex and striatum after middle cerebral artery (MCA) occlusion. Here we sought in vivo evidence of the ability of AM-36 to inhibit intrastriatal ROS generation and DA release after ischemia. Salicylate hydroxylation coupled with in vivo microdialysis in the striatum of conscious Long Evans rats was performed during MCA occlusion by perivascular microinjection of endothelin-1 (ET-1). AM-36 (6 mg/kg) was administered intraperitoneally 30 min after MCA occlusion. Dialysates were analysed using high performance liquid chromatography with electrochemical detection for the salicylate hydroxylation product, 2,3-dihydroxybenzoic acid (2,3 DHBA) and for DA and metabolites. MCA occlusion resulted in a marked increase in 2,3 DHBA and a secondary increase in all analytes, 180–300 min later. Increased DA release coincided with 2,3 DHBA formation. AM-36 significantly reduced ischemia induced increases in 2,3 DHBA and DA, and infarct volume in the striatum. Significant improvements in a battery of behavioural tests was also found in AM-36 treated rats. This study has demonstrated profound inhibition of ROS generation by a novel compound with antioxidant activity, administered post-ischemia in conscious rats.

Introduction

Reactive oxygen species (ROS) generation is considered to be an important contributor to neuronal damage in cerebral ischemia (Chan, 2001, Kuroda and Siesjo, 1997). Obtaining evidence for the involvement of ROS in the pathophysiology of cerebral ischemia has been difficult due to problems of directly measuring these species because of their extremely reactive nature and rapid degradation. However, methods relying on hydroxylation of compounds such as salicylate or 4-hydroxybenzoate by ROS to form stable detectable adducts (2,3 dihydroxybenzoic acid or 3,4-dihydroxybenzoate, respectively), have been utilised as an index of brain ROS formation (Floyd et al., 1984, Ste-Marie et al., 2000). Studies employing these techniques together with in vivo microdialysis, have detected increases in ROS in the hippocampus or striatum following transient global cerebral ischemia and reperfusion in rats (Globus et al., 1995, Piantadosi and Zhang, 1996, Ste-Marie et al., 2000, Yamamoto et al., 1997). Increases in ROS have also been demonstrated in the cortex (Gido et al., 2000, Morimoto et al., 1996, Solenski et al., 1997, Yang et al., 1996), and striatum (Lancelot et al., 1995, Li et al., 1997) in models of focal cerebral ischemia and reperfusion, suggesting a role for ROS in ischemia-induced neuronal damage. However, few studies have employed middle cerebral artery (MCA) occlusion models in rats (Bogaert et al., 2000, Li et al., 1997, Morimoto et al., 1996) and it is these models which are most pertinent to stroke in humans since the MCA is most commonly occluded (Garcia, 1984).

Antioxidants have been shown to attenuate ROS formation and neuronal damage in the reperfusion period in a global ischemia model (Yamamoto et al., 1997) however, there is limited data demonstrating a direct effect of antioxidants at reducing measured ROS formation during focal ischemia. Li et al. (1997) demonstrated that high doses of melatonin given prior to ischemia, inhibited production of hydroxyl radicals in the striatum of rats following MCA occlusion. However, these authors did not investigate subsequent neuroprotective effects of melatonin on ischemia-induced brain damage. Intracerebral administration of high concentrations of L-NAME, has been found to attenuate ROS generation in the cortex following a three-vessel occlusion model of focal ischemia (Solenski and Kwan, 2000). High systemic doses of the spin trapping agent PBN (alpha-phenyl-tert-butyl nitrone) were ineffective against hydroxyl radical formation in the cortex when administered before occlusion or immediately after reperfusion (Gido et al., 2000). To our knowledge, no previous studies have examined changes in ROS in conscious rats following focal ischemia by occlusion of the MCA, nor has attenuation of ROS generation by proven neuroprotective doses of an antioxidant compound been demonstrated post-ischemia.

There is ample evidence for an increase in extracellular glutamate in the brain following both global and focal ischemia (Beneviste et al., 1984, Hillered et al., 1989, Morimoto et al., 1996). However, increases in other neurotransmitters have also been detected, including dopamine (DA) (Bogaert et al., 2000, Phebus and Clemens, 1989). DA has been shown to contribute to subsequent neuronal damage following cerebral ischemia (Buisson et al., 1992, Clemens and Phebus, 1988, Globus et al., 1987). The susceptibility of the striatum to ischemia has been associated with DA oxidation (Allen et al., 1994, Chiueh et al., 1993, Ste-Marie et al., 2000) and increased vulnerability of the nigrostriatal pathway to oxidative stress (Chiueh et al., 1992). The striatum is generally considered to be the core of the ischemic lesion in rats and humans after MCA occlusion (Fisher and Garcia, 1996, Tyson et al., 1984) and previously has proved relatively refractory to neuroprotection. We have recently shown that AM-36 (1-(2-(4-chlorophenyl)-2-hydroxy)ethyl-4-(3,5-bis(1,1-dimethyl)-4-hydroxyphenyl)methylpiperazine), a novel neuroprotective agent with antioxidant and sodium (Na+) channel blocking activity (Callaway, 2001, Jarrott et al., 1997, Jarrott et al., 1999), can reduce ischemic damage in the striatum (Callaway et al., 1999). Blockade of Na+ channels has previously been shown to inhibit ischemia-induced glutamate and DA release in vitro (Taylor et al., 1995, Toner and Stamford, 1997) and in vivo (Lysko et al., 1994). Previous experiments in our laboratory, demonstrated inhibition by AM-36 of veratridine stimulated glutamate release from the cortex of anaesthetised rats in a concentration dependent manner (unpublished observations).

The purpose of the present study was to obtain in vivo evidence of antioxidant activity by determining whether AM-36 could inhibit salicylate hydroxylation in the dorsolateral striatum following MCA occlusion using the endothelin-1 (ET-1) method in conscious rats. Additionally, we sought evidence that AM-36 may inhibit the release of DA. The ET-1 model is less invasive than other models, incorporates gradual reperfusion, avoids damage to the endothelium by occlusion of the artery with filaments (Macrae, 1992) and has the advantage that rats are conscious during the stroke (Sharkey et al., 1993). The use of anaesthesia during stroke may confound experimental findings since barbiturates have been reported to be neuroprotective, may also potentially affect ROS production and inhibit neurotransmitter release (Bhardwaj et al., 1990). Inhalational anaesthetics such as isoflurane have also been reported to be neuroprotective (Warner et al., 1993).

The present studies report potent inhibition of ischemia-induced increases in salicylate hydroxylation and extracellular DA efflux by AM-36. These findings support the contribution of free radical scavenging and inhibition of transmitter release as the mechanism of action of AM-36 in protecting against neuronal damage and functional deficits in this rat model of stroke. Part of this work was presented at the 31st annual meeting of the Society for Neuroscience and at the 22nd annual meeting of the Australian Society for Neuroscience (Callaway and Jarrott, 2001b).

Section snippets

Animals

All procedures used in this study were carried out in accordance with the Prevention of Cruelty to Animals Act 1986 under the guidelines of the NH and MRC code of Practice for the Care and Use of Animals for Experimental Purposes in Australia. Male Long Evans rats (Monash University Animal Services, Australia) weighing 280–320 g were used throughout this study. These animals were housed in a room with controlled temperature (22±1 °C) and humidity (50±5%) under a 12:12 h light–dark cycle. Rats

Microdialysis

Basal striatal levels in nM (mean±SEM) in freely moving rats were 5.9±1.2 for 2,3 DHBA, 16.5±4.5 for DA, 15.3±7.2 for DOPAC and 21.4±7.8 for HVA (n=14). Since measured levels of 2,5 DHBA have been suggested to reflect microsomal P450 enzymatic hydroxylation of salicylate rather than in situ salicylate hydroxylation (Halliwell et al., 1991) the levels of 2,5 DHBA are not presented.

Fig. 1, Fig. 2 show the time course of 2,3 DHBA, DA, DOPAC and HVA outflow for 1 h prior, and 5 h following

Discussion

Only two studies have investigated changes in ROS generation in the striatum following focal cerebral ischemia (Lancelot et al., 1995, Li et al., 1997) and only the latter study employed an MCA occlusion model. The free radical scavenger, MCI-186, and the nitric oxide synthase inhibitor, L-NAME, have been shown to reduce 2,3 DHBA (the stable adduct of salicylate) formation in the cortex and hippocampus in models of transient cerebral ischemia in the rat (Yamamoto et al., 1997, Zhang et al., 1995

Concluding remarks

In conclusion, the present study has demonstrated in vivo evidence for inhibition of the generation of ROS following MCA occlusion-induced ischemia in conscious rats by AM-36. The mechanism of action is likely to be through antioxidant activity of this compound, but may also include inhibition of DA efflux possibly through blockade of neuronal Na+ channels. Correlations between 2,3 DHBA, DA and striatal damage, support inhibition of oxidative stress as a mechanism of neuroprotection in the

Acknowledgements

The authors gratefully acknowledge AMRAD Corporation Limited, Melbourne, Australia, for their contribution to the discovery and development of AM-36. This work was supported by the National Health and Medical Research Council, Australia.

References (78)

  • B Lei et al.

    The effect of dopamine depletion on the H2O2 production in the rat striatum following transient middle cerebral artery occlusion

    Brain Research

    (1997)
  • J Liu et al.

    Monoamine metabolism provides an antioxidant defense in the brain against oxidant- and fre radical-induced damage

    Archives of Biochemistry and Biophysics

    (1993)
  • L.A Phebus et al.

    Effects of transient, global, cerebral ischemia on striatal extracellular dopamine, serotonin and their metabolites

    Life Sciences

    (1989)
  • L.A Phebus et al.

    Iscemia increases tissue and decreases extracellular levels of acid dopamine metabolites in the rat striatum: further evidence for active transport of metabolites

    Life Sciences

    (1995)
  • N.J Solenski et al.

    Attenuation of free radical generation during reversible focal cerebral ischemia with the nitric oxide inhibitor, L-NAME (L-NG-nitro-l-arginine methyl ester)

    Brain Research

    (2000)
  • C.P Taylor et al.

    Sodium channels as targets for neuroprotective drugs

    Trends in Pharmacological Sciences

    (1995)
  • C.P Taylor et al.

    Hippocampal slices: glutamate overflow and cellular damage from ischemia are reduced by sodium channel blockade

    Journal of Neuroscience Methods

    (1995)
  • C.C Toner et al.

    Sodium channel blockade unmasks two temporally distinct mechanisms of striatal dopamine release during hypoxia/hypoglycaemia in vitro

    Neuroscience

    (1997)
  • T Yamaguchi et al.

    YM796, a novel muscarinic agonist, improves the impairment of learning behaviour in a rat model of chronic focal cerebral ischemia

    Brain Research

    (1995)
  • M Yamamoto et al.

    Behavioural changes after focal cerebral ischemia by left middle cerebral artery occlusion in rats

    Brain Research

    (1988)
  • T Yamamoto et al.

    Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia

    Brain Research

    (1997)
  • C.S Yang et al.

    In vivo evidence of hydroxyl radical formation induced by elevation of extracellular glutamate after cerebral ischemia in the cortex of anaesthetised rats

    Free Radicals in Biology and Medicine

    (1996)
  • I Zini et al.

    Detection of free radicals during brain ischemia and reperfusion by spin trapping and microdialysis

    Neuroscience Letters

    (1992)
  • J.S Beckman et al.

    Apparent hydroxyl radical production by peroxinitrite: implications for endothelial injury from nitric oxide and superoxide

    Proceedings of the National Academy of Sciences USA

    (1990)
  • H Beneviste et al.

    Elevation of the extracellular concentration of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis

    Journal of Neurochemistry

    (1984)
  • A Bhardwaj et al.

    Pentobarbital inhibits extracellular release of dopamine in the ischemic striatum

    Journal of Neural Transmission. General Section

    (1990)
  • C.M Brown et al.

    The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil

    British Journal of Pharmacology

    (1993)
  • A Buisson et al.

    Stiratal protection induced by lesioning of the substantia nigra of rats subjected to focal ischemia

    Journal of Neurochemistry

    (1992)
  • J.K Callaway

    Investigation of AM-36: a novel neuroprotective agent

    Clinical and Experimental Pharmacology and Physiology

    (2001)
  • J.K Callaway et al.

    AM-36 inhibits ischemia-induced free radical generation in the striatum of conscious rats

    Proceedings of the Australian Neuroscience Society

    (2001)
  • J.K Callaway et al.

    AM-36, a novel neuroprotective drug, inhibits both ischemia-induced increases in reactive oxygen species and dopamine release in the striatum of conscious rats

    Society for Neuroscience

    (2001)
  • J.K Callaway et al.

    Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats

    Stroke

    (1999)
  • J.K Callaway et al.

    Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis

    British Journal of Pharmacology

    (2001)
  • P.-E Chabrier et al.

    BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective stratery

    Proceedings of the National Academy of Sciences USA

    (1999)
  • P.H Chan

    Reactive oxygen radicals in signalling and damage in the ischemic brain

    Journal of Cerebral Blood Flow and Metabolism

    (2001)
  • C.C Chiueh et al.

    Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced Parkinsonism

  • M De Ryck et al.

    Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats

    Stroke

    (1989)
  • M Fisher et al.

    Evolving stroke and the ischemic penumbra

    Neurology

    (1996)
  • J.H Garcia

    Experimental ischemic stroke: a review

    Stroke

    (1984)
  • Cited by (27)

    • Size-controllable striatal lesion model for evaluation of neuroprotective agents in rats

      2013, Tzu Chi Medical Journal
      Citation Excerpt :

      The test scored based on the rats' baseline ability. Rats that did not fall off the rod within 10 minutes were given a maximum score of 600 seconds [16]. All data are presented as mean ± standard error of the mean.

    • Adaptive response to oxidative stress: Bacteria, fungi, plants and animals

      2011, Comparative Biochemistry and Physiology - C Toxicology and Pharmacology
      Citation Excerpt :

      In addition, minor ROS amounts are generated by some enzymes such as oxidases, through autooxidation of different molecules. The oxidases known producing ROS are NADPH oxidase, lipoxygenases, cyclooxygenases, and xanthine oxidase (Puddu et al., 2008), whereas molecules entering autooxidation may be exogenous and endogenous origination like neurotoxin 5-hydroxydecanoate (Rodriguez-Pallares et al., 2009) or catecholamines (Callaway et al., 2003) and many other compounds. Fig. 1 demonstrates ROS metabolism.

    • NADPH-oxidase activity is elevated in penumbral and non-ischemic cerebral arteries following stroke

      2006, Brain Research
      Citation Excerpt :

      Thus, the generation of large quantities of O2− by NADPH-oxidase in cerebral arteries following ischemia could have detrimental effects on the perfusion of the penumbra and thus contribute to delayed neuronal damage. However, as discussed, the generation of O2− by NADPH-oxidase is also enhanced in cerebral arteries from areas of the brain that do not have neuronal damage (Callaway et al., 2000, 2003; Macrae et al., 1993), suggesting that enhanced O2− generation by NADPH-oxidase does not necessarily lead to neuronal damage following cerebral ischemia. Intriguingly, we and others have reported that activation of cerebral vascular NADPH-oxidase results in the generation of O2− and/or H2O2, and elicits profound cerebral vasodilatation (Didion and Faraci, 2002; Miller et al., 2005; Paravicini et al., 2004, 2006; Park et al., 2004).

    View all citing articles on Scopus
    View full text